STUDIES ON DISSOLUTION ENHANCEMENT OF LOVASTATIN USING SOLUPLUS BY SOLID
... The present study is an attempt to improve the solubility and dissolution rate using solid dispersion of a poorly soluble drug Lovastatin by using Soluplus as carrier material to enhance the solubility as well as dissolution rate. Six different formulations were prepared using hot melt extrusion tec ...
... The present study is an attempt to improve the solubility and dissolution rate using solid dispersion of a poorly soluble drug Lovastatin by using Soluplus as carrier material to enhance the solubility as well as dissolution rate. Six different formulations were prepared using hot melt extrusion tec ...
Slide 1
... Secretion of prolactin is under the control of DOPAMINE (prolactin inhibiting hormone) secreted by hypothalamus ...
... Secretion of prolactin is under the control of DOPAMINE (prolactin inhibiting hormone) secreted by hypothalamus ...
Corporate Presentation
... (adults), Phase III (adults) expected initiation later in 2012; Phase II (pediatrics) initiated early 2012 Competitive Positioning: Expected to be first-to-market longacting hGH; Superb clinical, safety and immunogenicity profile, non-viscous drug product, granted orphan designation in the U.S. CMC ...
... (adults), Phase III (adults) expected initiation later in 2012; Phase II (pediatrics) initiated early 2012 Competitive Positioning: Expected to be first-to-market longacting hGH; Superb clinical, safety and immunogenicity profile, non-viscous drug product, granted orphan designation in the U.S. CMC ...
Takeda Takes Global Hematide Rights in $535m Affymax Deal
... Palo Alto-based Affymax will get US$105 million upfront from Osaka, Japan-based Takeda. If development goes well, Takeda will pay Affymax an additional $280 million plus up to US$150 million more for successful sales of the drug. The companies will co-commercialize Hematide in the United States. Tak ...
... Palo Alto-based Affymax will get US$105 million upfront from Osaka, Japan-based Takeda. If development goes well, Takeda will pay Affymax an additional $280 million plus up to US$150 million more for successful sales of the drug. The companies will co-commercialize Hematide in the United States. Tak ...
Pharmaceutical Chemistry - International Medical University
... Pharmaceutical chemistry is an interdisciplinary science that deals with drug design and synthesis, drug formulation and testing, as well as the delivery of drugs in the body. In view of the increase in the occurrence of existing and new diseases, continuous work in the discovery of new drugs that h ...
... Pharmaceutical chemistry is an interdisciplinary science that deals with drug design and synthesis, drug formulation and testing, as well as the delivery of drugs in the body. In view of the increase in the occurrence of existing and new diseases, continuous work in the discovery of new drugs that h ...
The Development of Novel Small Molecules as Protein Tyrosine
... One of the most familiar examples of PTK inhibition for cancer treatment is the targeting of Bcr-Abl, the mutant PTK resulted from a chromosomal translocation. The Philadelphia chromosome (Ph-chromosome), produced by the fusion of portions of chromosome 9 and chromosome 22, is the genetic cause of 9 ...
... One of the most familiar examples of PTK inhibition for cancer treatment is the targeting of Bcr-Abl, the mutant PTK resulted from a chromosomal translocation. The Philadelphia chromosome (Ph-chromosome), produced by the fusion of portions of chromosome 9 and chromosome 22, is the genetic cause of 9 ...
Phase `0` Clinical Trials or Exploratory Investigational New Drug
... including studies of closely related drugs or therapeutic biological products, under an IND application (21 CFR 312). Existing regulations allow a great deal of flexibility in the amount of data that needs to be submitted with an IND application, depending on the goals of the proposed investigation, ...
... including studies of closely related drugs or therapeutic biological products, under an IND application (21 CFR 312). Existing regulations allow a great deal of flexibility in the amount of data that needs to be submitted with an IND application, depending on the goals of the proposed investigation, ...
Nicotinics Monthly
... With respect to ADHD, we note that smokers were excluded from the Phase 2a study. Efficacy has not been investigated in patients who smoke although positive data in the schizophrenia study was driven by smokers. Smoking rates in adolescent and adult ADHD patients is high and TC-5619 may offer greate ...
... With respect to ADHD, we note that smokers were excluded from the Phase 2a study. Efficacy has not been investigated in patients who smoke although positive data in the schizophrenia study was driven by smokers. Smoking rates in adolescent and adult ADHD patients is high and TC-5619 may offer greate ...
View Program (as of 9/13/16) - Safety Pharmacology Society
... Canada, and Harushige Ozaki, Takeda Pharmaceutical Company Limited, Fujisawa, Kanagawa, Japan ...
... Canada, and Harushige Ozaki, Takeda Pharmaceutical Company Limited, Fujisawa, Kanagawa, Japan ...
ANTI-INFLAMMATORY ACTIVITY OF PLANTAGO EROSA WALL EXTRACTS IN RATS
... 34.92%, 47.62% and 58.73% inhibition of paw oedema respectively and were significant when compared to that of the control (p<0.001). The standard drug, aspirin (100 mg/kg) produced 61.90% inhibition of paw oedema. Higher doses of the test drug (200 mg and 400 mg/kg) showed comparable efficacy in red ...
... 34.92%, 47.62% and 58.73% inhibition of paw oedema respectively and were significant when compared to that of the control (p<0.001). The standard drug, aspirin (100 mg/kg) produced 61.90% inhibition of paw oedema. Higher doses of the test drug (200 mg and 400 mg/kg) showed comparable efficacy in red ...
PHAR 7633 Chapter 12 Physical-Chemical Factors
... For a drug to cross a membrane barrier it must normally be soluble in the lipid material of the membrane to get into membrane and it has to be soluble in the aqueous phase as well to get out of the membrane. Many drugs have polar and non-polar characteristics or are weak acids or bases. For drugs wh ...
... For a drug to cross a membrane barrier it must normally be soluble in the lipid material of the membrane to get into membrane and it has to be soluble in the aqueous phase as well to get out of the membrane. Many drugs have polar and non-polar characteristics or are weak acids or bases. For drugs wh ...
MAIN EXAM 2012 - University of KwaZulu
... SURNAME AND INITIALS (Optional): ________________________ SIGNATURE: _____________________ Student Number ...
... SURNAME AND INITIALS (Optional): ________________________ SIGNATURE: _____________________ Student Number ...
Withdrawal
... tolerance, two factors have been isolated with a degree of certainty. 1. Receptor Downregulation- Opioid receptors in the body are actively reduced due to overexposure to opioids. This can also have an effect on endogenous opioid peptide function (i.e. regular functioning of endorphins) 2. Antiopiat ...
... tolerance, two factors have been isolated with a degree of certainty. 1. Receptor Downregulation- Opioid receptors in the body are actively reduced due to overexposure to opioids. This can also have an effect on endogenous opioid peptide function (i.e. regular functioning of endorphins) 2. Antiopiat ...
Drug receptors and Pharmacodynamics
... Agonists may differ in how tightly they bind to their receptors (potency) and in the effect they produce (efficacy). Some drugs may bind very tightly (are highly potent) but produce only a modest effect (low efficacy). Low efficacy drugs are termed “partial agonists” while the structurally related d ...
... Agonists may differ in how tightly they bind to their receptors (potency) and in the effect they produce (efficacy). Some drugs may bind very tightly (are highly potent) but produce only a modest effect (low efficacy). Low efficacy drugs are termed “partial agonists” while the structurally related d ...
Cannabis sativa - Bakersfield College
... Symptoms are the opposite of the drug’s effects Body has made changes to compensate for drug’s presence – functions normally with the drug present Severity varies with drug and pattern of use ...
... Symptoms are the opposite of the drug’s effects Body has made changes to compensate for drug’s presence – functions normally with the drug present Severity varies with drug and pattern of use ...
Predicting drug-target interaction in cancers using homology
... experience adverse effects. As a result, the vast majority of the population is denied the benefits of these drugs, to protect a relatively small percentage of non-responders. The SNP at the genome level that encodes for the substrate binding domain may alter the amino acid which effects KI. The KI ...
... experience adverse effects. As a result, the vast majority of the population is denied the benefits of these drugs, to protect a relatively small percentage of non-responders. The SNP at the genome level that encodes for the substrate binding domain may alter the amino acid which effects KI. The KI ...
Prescription Stimulants (Canadian Drug Summary)
... blood flow and oxygen to the heart, at the same time causing an increase in blood pressure and heart rate. Stimulants also increase body temperature and breathing rate, as well as decrease the ability to sleep and the desire to eat. Other short-term effects can include sweating, dilated pupils, rest ...
... blood flow and oxygen to the heart, at the same time causing an increase in blood pressure and heart rate. Stimulants also increase body temperature and breathing rate, as well as decrease the ability to sleep and the desire to eat. Other short-term effects can include sweating, dilated pupils, rest ...
CHM 326 LECTURE NOTE
... Natural Products is define as organic compounds and other chemicals synthesised by plants through metabolic processes aided by sunlight, involving CO2, H2O vapour and chlorophyll. Generally, natural products are characterised by specific functions they perform in plants and animals. Categories of na ...
... Natural Products is define as organic compounds and other chemicals synthesised by plants through metabolic processes aided by sunlight, involving CO2, H2O vapour and chlorophyll. Generally, natural products are characterised by specific functions they perform in plants and animals. Categories of na ...
ARGYREIA NERVOSA Research Article KAMAL JEET
... activity of ethyl acetate and methanol extracts of whole aerial part from Argyreia nervosa in yeast induced pyrexia rats. The different doses of the extracts were administered to various groups of animals as per the acute toxicity study. The results of antipyretic activity are shown in Table 4. The ...
... activity of ethyl acetate and methanol extracts of whole aerial part from Argyreia nervosa in yeast induced pyrexia rats. The different doses of the extracts were administered to various groups of animals as per the acute toxicity study. The results of antipyretic activity are shown in Table 4. The ...
The Concept of Chemical Similarity for Optimization and Design of
... • the actual fuel or solid reactant of the industrial-scale process has to be used in the laboratory-scale • artificial fuels or solid reactants with well-known compositions can be used as model fuels for the calibration of test units But even if the same solid reactant is used in laboratory-scale t ...
... • the actual fuel or solid reactant of the industrial-scale process has to be used in the laboratory-scale • artificial fuels or solid reactants with well-known compositions can be used as model fuels for the calibration of test units But even if the same solid reactant is used in laboratory-scale t ...
Sustained release drug delivery system
... form is controlled mainly by the type and proportion of polymer used in the reparations. Hydrophilic polymer matrix is widely used for formulating an SR dosage form2-5. Because of increased complication and expense involved in marketing of new drug entities, has focused greater attention on developm ...
... form is controlled mainly by the type and proportion of polymer used in the reparations. Hydrophilic polymer matrix is widely used for formulating an SR dosage form2-5. Because of increased complication and expense involved in marketing of new drug entities, has focused greater attention on developm ...
- The University of Liverpool Repository
... and schizophrenia (Table 1) [9-11]. The advent of the HIV LA medicines has been greeted with great excitement within the scientific, clinical and patient communities. In the short term, since only single agent LA medicines will be available, the largest impact is likely to be made by their deploymen ...
... and schizophrenia (Table 1) [9-11]. The advent of the HIV LA medicines has been greeted with great excitement within the scientific, clinical and patient communities. In the short term, since only single agent LA medicines will be available, the largest impact is likely to be made by their deploymen ...
chemical diversion and synthetic drug manufacture
... The monitoring and control of precursor and other chemicals used in the manufacture of illicit drugs are recognized as a significant supply and demand reduction initiative in a comprehensive strategy to tackle drug abuse and trafficking. Both Canada and the United States are signatories to, and have ...
... The monitoring and control of precursor and other chemicals used in the manufacture of illicit drugs are recognized as a significant supply and demand reduction initiative in a comprehensive strategy to tackle drug abuse and trafficking. Both Canada and the United States are signatories to, and have ...
Pharmacology
... • Primates may be given the drug to show that effects in them are similar to smaller (cheaper) animals. • The use of primates in animal research is becoming more rare; used only when necessary • Ex. when a smaller animal does not have a disease found in humans, such as HIV ...
... • Primates may be given the drug to show that effects in them are similar to smaller (cheaper) animals. • The use of primates in animal research is becoming more rare; used only when necessary • Ex. when a smaller animal does not have a disease found in humans, such as HIV ...
Drug discovery
In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which new candidate medications are discovered. Historically, drugs were discovered through identifying the active ingredient from traditional remedies or by serendipitous discovery. Later chemical libraries of synthetic small molecules, natural products or extracts were screened in intact cells or whole organisms to identify substances that have a desirable therapeutic effect in a process known as classical pharmacology. Since sequencing of the human genome which allowed rapid cloning and synthesis of large quantities of purified proteins, it has become common practice to use high throughput screening of large compounds libraries against isolated biological targets which are hypothesized to be disease modifying in a process known as reverse pharmacology. Hits from these screens are then tested in cells and then in animals for efficacy.Modern drug discovery involves the identification of screening hits, medicinal chemistry and optimization of those hits to increase the affinity, selectivity (to reduce the potential of side effects), efficacy/potency, metabolic stability (to increase the half-life), and oral bioavailability. Once a compound that fulfills all of these requirements has been identified, it will begin the process of drug development prior to clinical trials. One or more of these steps may, but not necessarily, involve computer-aided drug design. Modern drug discovery is thus usually a capital-intensive process that involves large investments by pharmaceutical industry corporations as well as national governments (who provide grants and loan guarantees). Despite advances in technology and understanding of biological systems, drug discovery is still a lengthy, ""expensive, difficult, and inefficient process"" with low rate of new therapeutic discovery. In 2010, the research and development cost of each new molecular entity (NME) was approximately US$1.8 billion. Drug discovery is done by pharmaceutical companies, with research assistance from universities. The ""final product"" of drug discovery is a patent on the potential drug. The drug requires very expensive Phase I, II and III clinical trials, and most of them fail. Small companies have a critical role, often then selling the rights to larger companies that have the resources to run the clinical trials.Discovering drugs that may be a commercial success, or a public health success, involves a complex interaction between investors, industry, academia, patent laws, regulatory exclusivity, marketing and the need to balance secrecy with communication. Meanwhile, for disorders whose rarity means that no large commercial success or public health effect can be expected, the orphan drug funding process ensures that people who experience those disorders can have some hope of pharmacotherapeutic advances.